JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: A review of its behavioural properties

Pharmacological Research

Volumn 36, Issue 4, 1997, Pages 255-264

  Bruhwyler, Jacques ^a   Liégeois, Jean François ^b   Bergman, Jack ^c   Carey, Galen ^c   Goudie, Andrew ^d   Taylor, Anita ^d   Meltzer, Herbert ^e   Delarge, Jacques ^b   Géczy, Joseph ^a  

^a Therabel Pharma Belgium   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c MCLEAN HOSPITAL   (United States)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

Atypical antipsychotic; Behavioural pharmacology; Clozapine; JL13

Indexed keywords

BENZOXEPIN DERIVATIVE; CLOZAPINE; JL 13; NEUROLEPTIC AGENT; UNCLASSIFIED DRUG;

BEHAVIOR; CLIMBING; DOG; FORCED SWIMMING TEST; HYPERACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; RODENT; SQUIRREL MONKEY; STEREOTYPY;

EID: 0031258355     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1997.0231     Document Type: Article

References (71)

1. 1. Kane J. Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential. Drugs 1993; 46: 585-93.
2. 2. Kane J, Honigfeld G, Singer J, Meltzer HY. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988; 45: 789-96.
3. 3. Marder SR, Ames D, Wirshing WC, Van Putten T. Schizophrenia. Psychiatr Clin North Am 1993; 16: 567-87.
4. 4. Lieberman JA, Johns CA, Kane JM, Rai K, Pisciotta AV, Saltz BL, Howard A. Clozapine-induced agranulocytosis: non-cross reactivity with other psychotropic drugs. J Clin Psychiatry 1988; 49: 271-7.
5. 5. Pisciotta AV. Drug induced agranulocytosis peripheral destruction of polymorphonuclear leukocytes and their marrow precursors. Blood Rev 1990; 4: 226-37.
6. 6. Krupp P, Barnes P. Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology 1989; 99: S118-21.
7. 7. Fitton A, Benfield P, Clozapine. An appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia. Pharmacoeconomics 1993; 4: 131-56.
8. 8. Toth P, Frankenburg FR. Clozapine and seizures: a review. Can J Psychiatry 1994; 39: 236-8.
9. 9. Wilson WH, Claussen AM. Seizures associated with clozapine treatment in a state hospital. J Clin Psychiatry 1994; 55: 184-8.
10. 10. Deutch AY, Moghaddam B, Innis RB, Krystal JH, Aghajanian GK, Bunney BS, Charney DS. Mechanisms of action of atypical antipsychotic drugs. Schizophrenia Res 10: 4: 121-56.
11. 11. Tricklebank MD, Bristow LJ, Hutson PH. Progress in drug research. In: Ersnst J. ed. Fortschritte der Arzneimittel Forschung. Birkhaüser Verlag, Basel, Boston, Berlin, vol. 38, 1992; pp. 299-336.
12. 12. Liégeois JF, Bruhwyler J, Rogister F, Delarge J. Diarylazepine derivatives as potent atypical neuroleptic drugs: recent advances. Curr Med Chem 1995; 1: 471-501.
13. 13. Baldessarini RJ Drugs and the treatment of psychiatric disorders. In: Goodman Gilman A, Rall TW, Nies AS, Taylor P eds. The Pharmacological Basis of Therapeutics. Pergamon Press, New York, 1990; pp. 391-447.
14. 14. DeGraaf JS, VanRiezen H, Berendsen HHG, Van-Delft AML. A set of behavioural tests predicting antidepressant activity. Drug Dev Res 1985; 5: 291-301.
15. 15. Bruhwyler J, Chleide E, Mercier M. Clozapine: an atypical neuroleptic. Neurosci Biobehav Rev 1990; 14: 357-63.
16. 16. Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl J Med 1991; 324: 746-54.
17. 17. Liégeois JF, Bruhwyler J, Damas J, Nguyen TP, Chleide E, Mercier M, Rogister F, Delarge J. New pyridobenzodiazepine derivatives as potential antipsychotics: synthesis and neurochemical study. J Med Chem 1993; 36: 2107-14.
18. 18. Liégeois JFF, Rogister FA, Bruhwyler J, Damas J, Nguyen TP, Inarejos MO, Chleide EMG, Mercier MGA, Delarge JE. Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: synthesis and neurochemical study. J Med Chem 1994; 37: 519-25.
19. 19. Janssen PAJ, Niemegeers CJC, Jagenau A. Apomorphine-antagonism in rats. Arzneim Forsch 1960; 10: 1003-6.
20. 20. Protais P, Costentin J, Schwartz JC. Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum. Psychopharmacology 1976; 50: 1-6.
21. 21. Bruhwyler J. Anxiolytic potential of a microgram dose of chlordiazepoxide in the open-field test. Eur J Pharmacol 1990; 187: 547-9.
22. 22. Bruhwyler J, Chleide E, Liégeois JF, Delarge J, Mercier M. Effects of specific dopaminergic agonists and antagonists in the open-field test. Pharmacol Biochem Behav 1991; 39: 367-71.
23. 23. Bruhwyler J, Chleide E, Houbeau G, Mercier M. Stimulant effect of the beta-carboline FG 7142 in the open-field test. Eur J Pharmacol 1991; 200: 183-5.
24. 24. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977; 229: 327-36.
25. 25. Bruhwyler J, Chleide E Comparative study of the behavioural, neurophysiological and motor effects of psychotropic drugs in the dog. Biol Psychiatry 1990; 27: 1264-78.
26. 26. Bruhwyler J, Liégeois JF, Chleide E, Rogister F, Damas J, Delarge J, Mercier M. Comparative study of typical neuroleptics, clozapine and newly synthesized clozapine-analogues: correlations between neurochemistry and behaviour. Behav Pharmacol 1992; 3: 567-79.
27. 27. Bruhwyler J, Chleide E, Rettori MC, Poignant JC, Mercier M. Amineptine improves the performance of dogs in a complex temporal regulation schedule. Pharmacol Biochem Behav 1993; 45: 897-903.
28. 28. Bruhwyler J, Chleide E, Houbeau G, Waegeneer N, Mercier M. Differentiation of haloperidol and clozapine using a complex operant schedule in the dog. Pharmacol Biochem Behav 1993; 44: 181-9.
29. 29. Cohen M. Effects of orally administered psychotropic drugs on dog conditioned avoidance responses. Arch Int Pharmacodyn Ther 1981; 253: 11-21.
30. 30. Goudie AJ, Leathley MJ. Drug-discrimination assays. In: Saghal A. ed. Behavioural Neuroscience: A Practical Approach, Vol II. IRL Press, Oxford, 1993; pp. 145-68.
31. 31. Extance K, Goudie AJ. Inter-animal cues in operant drug discrimination assays in rats. Psychopharmacology 1981; 73: 63-70.
32. 32. Spealman RD, Goldberg SR, Kelleher RT, Goldberg DM, Charlton JP. Some effects of cocaine and two cocaine analogs on schedule-controlled behavior of squirrel monkeys. J Pharmacol Exp Ther 1977; 202: 500-9.
33. 33. Bruhwyler J, Liégeois JF, Lejeune C, Rogister F, Delarge J, Géczy J. New dibenzazepine derivatives with disinhibitory and/or antidepressant potential: neurochemical and behavioural study in the open-field and forced swimming tests. Behav Pharmacol 1995; 6: 830-8.
34. 34. Browne RG, Koe BK. Clozapine and agents with similar behavioral and biochemical properties. In: Colpaert FC, Slangen JL. eds. Drug Discrimination: Applications in CNS Pharmacology. Elsevier Biomedical Press, Amsterdam, 1982; pp. 241-54.
35. 35. Nielsen EB. Cholinergic mediation of the discriminative stimulus properties of clozapine. Psychopharmacology 1988; 94: 115-18.
36. 36. Wiley JL, Porter JH. Serotonergic drugs do not substitute for clozapine in clozapine-trained rats in a two-lever drug discrimination procedure. Pharmacol Biochem Behav 1992; 43: 961-5.
37. 37. Moore NA, Calligaro DO, Wong DT, Bymaster F, Tye NC. The pharmacology of olanzapine and other new antipsychotic drugs. Curr Opin Invest Drugs 1993; 2: 281-93.
38. 38. Taylor A, Goudie AJ, Smith JA. Treatment strategies in schizophrenia, British Pharmacology Society, December 1996.
39. 39. Carey GJ, Bergman J. Discriminative-stimulus effects of clozapine in squirrel monkeys: comparison with conventional and novel antipsychotic drugs. Psychopharmacology 1997; 132: 261-3.
40. 40. Carlsson A. Mechanism of action of neuroleptic drugs. In: Lipton MA, DiMascio A, Killam KF. eds. Psychopharmacology: A Generation of Progress. Raven Press , New York, 1978; pp. 509-29.
41. 41. Groves PM, Rebec GV. Biochemistry and behavior: some central actions of amphetamine and antipsychotic drugs. Ann Rev Psychol 1976; 27: 91-127.
42. 42. Bartholini G, Haefely W, Jalfre M, Keller HH, Pletscher A. Effects of clozapine on cerebral catecholaminergic neuron systems. Br J Pharmacol 1972; 46: 736-40.
43. 43. Iversen SD, Koob GF. Behavioral implications of dopaminergic neurons in the mesolimbic system. In: Costa E, Gessa GL. eds. Nonstriatal Dopaminergic Neurons. Advances in Biochemical Psychopharmacology, Raven Press, New York, 1977; pp. 209-14.
44. 44. Ljungberg T. Ungerstedt Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing: evidence for two different mechanisms of action. Psychopharmacology 1978; 56: 239-47.
45. 45. Coward DM. General pharmacology of clozapine. Br J Psychiatry 1992; 160: 5-11.
46. 46. Kelly PH, Iversen SD. Selective 6-OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats. Eur J Pharmacol 1976; 40: 45-56.
47. 47. Darmani NA, Martin BR, Glennon RA. Behavioral evidence for differential adaptation of the serotonergic system after acute and chronic treatment with ( + / - )-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) or ketanserin. J Pharmacol Exp Ther 1992; 262: 692-8.
48. 48. Darmani NA, Mock OB, Towns LC, Gerdes CF. The head-twitch response in the least shrew (Cryptotis parva) is a 5-HT2- and not a 5-HT1C-mediated phenomenon. Pharmacol Biochem Behav 1994; 48: 383-96.
49. i values. J Pharmacol Exp Ther 1989; 251: 238-46.
50. 50. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Shen Y, Meltzer HY, Sibley DR. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994; 268: 1403-10.
51. 51. Canton H, Verrièle L, Colpaert FC. Binding of typical and atypical antipsychotics to 5-HT1C and 5-HT2 sites: Clozapine potently interacts with 5-HT1C sites. Eur J Pharmacol 1990; 191: 93-6.
52. 52. Schreiber R, Brocco M, Millan MJ. Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone. Eur J Pharmacol 1994; 264: 99-102.
53. 2 receptor activation. Psychopharmacology 1988; 94: 263-6.
54. 54. Seeman P, Van Tol HHM. Dopamine receptor pharmacology. Trends Pharmacol Sci 1994; 15: 264-70.
55. 2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur J Pharmacol 1993; 236: 483-6.
56. 56. Philips ST, De Paulis T, Baron BM, Siegel BW, Seeman P, Van Tol HHM, Guan HC, Smith HE. Binding of 5H-dibenzo[b,e][1,4]diazepine and chiral 5H-dibenzo[a,d]cycloheptene analogues of clozapine to dopamine and serotonin receptors. J Med Chem 1994; 37: 2686-96.
57. 57. Sorensen SM, Kehne JH, Fadayel GM, Humpreys TM, Ketteler HL, Sullivan CK, Taylor VL, Schmidt CJ. Characterization of the 5-HT2 receptor antagonist MDL 100,907 a putative atypical antipsychotic: behavioural, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 1993; 266: 684-91.
58. 58. Schmidt CJ, Sorensen SM, Kehne JH, Carr AA, Palfreyman MG. The role of 5-HT2A receptors in antipsychotic activity. Life Sci 1995; 56: 2209-22.
59. 59. De Vrij J, Benz U, Schreiber R, Traber J. Shock-induced ultrasonic vocalization in young adult rats: a model for testing putative anti-anxiety drugs. Eur J Pharmacol 1993; 249: 331-9.
60. 60. Wiley JL, Compton AD, Porter JH. Effects of four antipsychotics on punished responding in rats. Pharmacol Biochem Behav 1993; 45: 263-7.
61. 61. Moore NA, Rees G, Sanger G, Tye NC. Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav Pharmacol 1994; 5: 196-202.
62. 62. Benvenga MJ, Leander JD. Olanzapine, an atypical antipsychotic, increases rates of punished responding in pigeons. Psychopharmacology 1995; 119: 133-8.
63. 63. Meert TF. A comparative study of the effects of ritanserin (R55667) and chlordiazepoxide on rat open field behavior. Drug Dev Res 1986; 8: 197-204.
64. 64. Awouters F, Niemegeers CJE, Megens AAHP, Meert TF, Janssen PAJ. Pharmacological profile of ritanserin: a very specific central serotonin S2-antagonist. Drug Dev Res 1988; 15: 61-73.
65. 65. Stutzmann JM, Eon B, Darche F, Lucas M, Rataud J, Piot O, Blanchard JC, Laduron PM. Are 5-HT2 antagonists endowed with anxiolytic properties in rodents? Neurosci Lett 1991; 128: 4-8.
66. 66. Canon JG, Lippa AS. Use of DRL in differentiating anxiolytic and neuroleptic properties of CNS drugs. Pharmacol Biochem Behav 1977; 6: 591-3.
67. 67. Spealman RD, Kelleher RT, Goldberg SR, DeWeese J, Goldberg DM. Behavioural effects of clozapine: comparison with thioridazine, chlorpromazine, haloperidol and chlordiazepoxide in squirrel monkeys. J Pharmacol Exp Ther 1983; 224: 127-34.
68. 68. Van Hest A, Van Drimmelen M, Olivier B. Flesinoxan shows antidepressant activity in a DRL 72-s screen. Psychopharmacology 1992; 107: 474-9.
69. 69. Richards JB, Sabol KE, Hand TH, Jolly DC, Marek GJ, Seiden LS. Buspirone, gepirone, ipsapirone, and zalospirone have distinct effects on the differential-reinforcement-of-low-rate 72-s schedule when compared with 5-HTP and diazepam. Psychopharmacology 1994; 114: 39-46.
70. 70. Jackson A, Koek W, Colpaert FC. Can the DRL 72s schedule selectively reveal antidepressant drug activity? Psychopharmacology 1995; 117: 154-61.
71. 71. Koek W, Jackson A, Colpaert FC. Behavioural pharmacology of antagonists of 5HT2/5HT1C receptors. Neurosci Biobehav Rev 1992; 16: 95-105.